Elsevier

Bone

Volume 120, March 2019, Pages 114-124
Bone

Full Length Article
Systemic bone loss, impaired osteogenic activity and type I muscle fiber atrophy in mice with elastase-induced pulmonary emphysema: Establishment of a COPD-related osteoporosis mouse model

https://doi.org/10.1016/j.bone.2018.10.017Get rights and content

Highlights

  • Elastase-induced pulmonary emphysema mice showed systemic bone loss.

  • Elastase-induced pulmonary emphysema mice showed impaired bone formation.

  • Elastase-induced pulmonary emphysema mice showed type I muscle fiber atrophy.

  • Emphysema may systemically induce bone/type I fiber loss and impair bone formation.

  • The model in our study may be useful as a COPD/emphysema-related osteoporosis model.

Abstract

Although it is suggested that chronic obstructive pulmonary disease (COPD) and bone are related, almost all of the pathological mechanisms of COPD-related osteoporosis remain unknown. There is a mouse model showing a deterioration of bone quality after cigarette smoke exposure; however, in smoking exposure models, various factors exist that affect bone metabolism, such as smoking and body weight loss (muscle and fat mass loss). We considered it appropriate to use an elastase-induced emphysema model to exclude factors influencing bone metabolism and to investigate the influence of pulmonary emphysema on bone metabolism. The purpose of this study was to establish a COPD/emphysema-related osteoporosis mouse model by using the elastase-induced emphysema model. The lumbar vertebrae and femurs/tibiae exhibited trabecular bone loss and impaired osteogenic activity in 24-week-old male elastase-induced emphysema model mice. In addition, the model mice showed atrophy of type I muscle fibers without atrophy of type II muscle fibers. We believe that the mice described in this experimental protocol will be accepted as a COPD/emphysema-related osteoporosis mouse model and contribute to further investigations.

Introduction

Chronic obstructive pulmonary disease (COPD) demonstrates skeletal muscle and bone disorders as extrapulmonary lesions and is a risk factor for osteoporosis and sarcopenia [[1], [2], [3], [4], [5], [6], [7], [8]]. Patients diagnosed with COPD have a high prevalence of osteoporosis [9]. The prevalence of vertebral fractures in COPD patients is 24 to 63% [10], and thoracic vertebral fractures occur more often than lumbar vertebral fractures [11]. In addition, COPD is the most frequent disease as a cause of secondary osteoporosis in men [12].

Chronic inflammation due to many factors occurs in the lungs of patients with COPD, and irreversible loss of alveolar surface and depletion of lung elastin, which are pulmonary emphysema findings, have been identified [13]. There is also a clinical phenotype called combined pulmonary fibrosis and emphysema (CPFE), which is characterized by the coexistence of pulmonary fibrosis and emphysema [14], but emphysema volume has especially been shown to be strongly related to vertebral bone mineral density (BMD) [15]. Almost all of the pathological mechanisms of COPD/emphysema-related osteoporosis remain unknown, although it is suggested that COPD/emphysema is related to bone.

The problem in investigating the pathological mechanism of COPD-related osteoporosis is that various factors exist that affect bone metabolism, such as smoking [16], body weight [17], COPD exacerbation [18], use of steroids [19], and sarcopenia [20]. In particular, sarcopenia and body weight loss in COPD subjects are related to excessive energy expenditure by respiratory muscles, systemic inflammation, nutrition disability and physical inactivity. Analysis excluding these factors is difficult in humans, and analysis in an animal model is desired; however, there is currently an absence of an appropriate animal model for COPD/emphysema-related osteoporosis patients.

Several pulmonary emphysema models exist [21], such as smoking exposure models, transgenic animals, and elastase-induced emphysema models. The smoking exposure model is the one most commonly used as a COPD animal model, and it demonstrates the deterioration of bone quality [22]. However, there is no unified experimental protocol [23]. In addition, the degree of emphysema is mild; therefore, it may be the influence of smoking exposure rather than emphysema causing bone to degrade. Problematically, not only weight but also fat and muscle mass decrease systemically over time [24]. In transgenic animals, we must consider the effect of genetic modifications on bone. An elastase-induced emphysema model is used to initiate the inflammatory response seen in COPD and to induce an inflammatory response to make it permanent [23]. The greatest advantage is that we can control the severity of pulmonary emphysema depending on the elastase dosage. Therefore, we considered it appropriate to use this model to exclude factors influencing bone metabolism (smoking, body weight loss, muscle mass loss) and to investigate the influence of COPD/emphysema on bone metabolism.

It is necessary for us develop a mouse model to elucidate the pathological mechanisms of a COPD/emphysema-related osteoporosis. We planned the following study, utilizing the elastase-induced emphysema model to establish an appropriate animal model for patients with COPD/emphysema-related osteoporosis. The purposes of our study are 1) to verify the elastase dosage that induces the emphysema without complications (weakness and body weight loss) and 2) to evaluate the bones and muscles of the pulmonary emphysema model mice. In addition, this study establishes a mouse model of patients with COPD/emphysema-related osteoporosis.

Section snippets

Mice

The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of the University of Occupational and Environmental Health (approval number, AE11-014). A total of 56 eight-week-old male C57BL/6 J mice (approximately 20 g) were purchased from Charles River Japan (Tokyo, Japan) and acclimated for 4 weeks under standard laboratory conditions (temperature 24 ± 1 °C, humidity 55 ± 5%). All of the mice were housed in similarly designed cages. The light/dark cycle was

Body weight

The experimental protocol design is shown in Fig. 1A. Seven of the 14 mice in the PPE 0.25 group were euthanized after a few days due to weakness. Four of the remaining 7 mice showed body weight losses of 15% or more at day 7 after intratracheal administration; thus, the experiment was stopped for the PPE 0.25 group. There were no significant differences in body weight at each week among the Control, PPE 0.025, and PPE 0.1 groups (Fig. 1B).

Lung histomorphometry

The effect of PPE administration into the trachea on

Discussion

This study was performed to establish a COPD/emphysema-related osteoporosis mouse model for elucidating the pathological mechanism of COPD/emphysema-related osteoporosis, and the following results were observed according to the purposes of this study. 1) PPE 0.025 U and PPE 0.1 U were the appropriate doses (Fig. 1 B–D) when we examined the elastase dose that induced emphysema without complications. Therefore, the bone and muscle data were compared among the PPE 0.1, PPE 0.025 and Control

Conclusions

The bone and muscle phenotypes in the mice with elastase-induced emphysema were highly similar to those previously reported in patients with COPD. We believe that the mice described in this experimental protocol will be accepted as a COPD/emphysema-related osteoporosis model.

The following is the supplementary data related to this article.

Disclosures

None of the authors have conflicts of interest to disclose.

Acknowledgments

The authors greatly appreciate the technical assistance of Nao Terada (Department of Orthopaedic Surgery), Minako Nimura (Department of Orthopaedic Surgery) and Ryoko Maekado (Shared-Use Research Center) from the University of Occupational and Environmental Health. This work was supported, in part, by a Grant-in-Aid for Scientific Research (JSPS KAKENHI Grant Number JP 16H07390) and Japan Osteoporosis Society 2018 Research Encouragement Award.

References (48)

  • K.F. Rabe et al.

    Update in chronic obstructive pulmonary disease 2006

    Am. J. Respir. Crit. Care Med.

    (2007)
  • T.T. Dam et al.

    Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma

    Osteoporos. Int.

    (2010)
  • J.M. Duckers et al.

    Low bone mineral density in men with chronic obstructive pulmonary disease

    Respir. Res.

    (2011)
  • K. Schnell et al.

    The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999–2008

    BMC Pulm. Med.

    (2012)
  • S. Bernard et al.

    Peripheral muscle weakness in patients with chronic obstructive pulmonary disease

    Am. J. Respir. Crit. Care Med.

    (1998)
  • J.M. Seymour et al.

    The prevalence of quadriceps weakness in COPD and the relationship with disease severity

    Eur. Respir. J.

    (2010)
  • R. Watanabe et al.

    Osteoporosis is highly prevalent in Japanese males with chronic obstructive pulmonary disease and is associated with deteriorated pulmonary function

    J. Bone Miner. Metab.

    (2015)
  • L. Graat-Verboom et al.

    Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures

    J. Bone Miner. Res.

    (2011)
  • C.S. Ryan et al.

    Osteoporosis in men: the value of laboratory testing

    Osteoporos. Int.

    (2011)
  • J.J. Atkinson et al.

    Matrix metalloproteinase-9 in lung remodeling

    Am. J. Respir. Cell Mol. Biol.

    (2003)
  • V. Cottin et al.

    Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity

    Eur. Respir. J.

    (2005)
  • K.D. Ward et al.

    A meta-analysis of the effects of cigarette smoking on bone mineral density

    Calcif. Tissue Int.

    (2001)
  • L. Graat-Verboom et al.

    Current status of research on osteoporosis in COPD: a systematic review

    Eur. Respir. J.

    (2009)
  • H. Kiyokawa et al.

    Impact of COPD exacerbations on osteoporosis assessed by chest CT scan

    COPD

    (2012)
  • Cited by (18)

    • Preliminary therapeutic and mechanistic evaluation of S-allylmercapto-N-acetylcysteine in the treatment of pulmonary emphysema

      2021, International Immunopharmacology
      Citation Excerpt :

      Usually, the airway and/or alveolar expansions of COPD are caused by critical exposures to noxious particles or gases, such as tobacco or cigarette smoke, which can induce emphysema, inflammation, oxidative stress and protease/anti-protease imbalance and so on [1]. Similarly, elastase can induce pulmonary emphysema, alveolar expansions and inflammatory responses [3]. In the elastase-challenged mice, macrophages, neutrophils, and T cells in the bronchoalveolar lavage fluid (BALF) are increased while pro-inflammatory cytokines (TNF-α, IL-6), chemokines (MIP-2) and growth factors (GCSF) are elevated [4,5].

    • S-Allylmercapto-N-acetylcysteine ameliorates elastase-induced chronic obstructive pulmonary disease in mice via regulating autophagy

      2021, Biochemical and Biophysical Research Communications
      Citation Excerpt :

      Although tobacco smoking are the primary cause contributing to COPD [15,16], the emphysema model established by cigarette smoke exposure or intraperitoneal injection of cigarette smoke extract might probably terminate or weaken once the stimulation is eliminated [17]. Therefore, an elastase-induced COPD model was set up, which can cause inflammation and pulmonary emphysema rapidly, and maintain the pathological features for relatively longer period after treatments [18–20]. Chronic inflammation caused by the activation and aggregation of inflammatory cells is the characteristic of COPD.

    • Metabolomics profiling reveals Echinops latifolius Tausch improves the trabecular micro-architecture of ovariectomized rats mainly via intervening amino acids and glycerophospholipids metabolism

      2020, Journal of Ethnopharmacology
      Citation Excerpt :

      Osteoporosis is a metabolic bone disease characterized by pathological bone loss, bone strength reduction, and microarchitectural deterioration of bone tissue (Alexandre and Vico, 2011; Kerschan-Schindl, 2016; Tsukamoto et al., 2019).

    • Transient receptor potential vanilloid 1 and 4 double knockout leads to increased bone mass in mice

      2020, Bone Reports
      Citation Excerpt :

      In addition, the bone mineral density (BMD) of the right femurs was evaluated by dual-energy X-ray absorptiometry (DXA; DCS-600, Aloka, Tokyo, Japan). The trabecular bone and cortical bone in the right femur of WT and DKO mice were evaluated through microcomputed tomography (micro-CT), as previously described (Tsukamoto et al., 2019a,b). A micro-CT system (CosmoScan GX; Rigaku, Tokyo, Japan) was used, and the minimum threshold for bone was 304 mg/cm3.

    View all citing articles on Scopus
    1

    Present/permanent address: Department of Orthopaedic Surgery, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan.

    View full text